Viridian Therapeutics Inc (NASDAQ:VRDN) has a beta value of 1.11 and has seen 1.13 million shares traded in the last trading session. The company, currently valued at $1.08B, closed the last trade at $17.21 per share which meant it lost -$0.13 on the day or -0.75% during that session. The VRDN stock price is -76.06% off its 52-week high price of $30.30 and 36.49% above the 52-week low of $10.93. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.2 million shares traded. The 3-month trading volume is 976.79K shares.
Viridian Therapeutics Inc (NASDAQ:VRDN) trade information
Sporting -0.75% in the red in last session, the stock has traded in the red over the last five days, when the VRDN stock price touched $17.21 or saw a rise of 4.44%. Year-to-date, Viridian Therapeutics Inc shares have moved -20.98%, while the 5-day performance has seen it change -2.22%. Over the past 30 days, the shares of Viridian Therapeutics Inc (NASDAQ:VRDN) have changed -7.42%. Short interest in the company has seen 7.57 million shares shorted with days to cover at 8.98.
Viridian Therapeutics Inc (VRDN) estimates and forecasts
Figures show that Viridian Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -0.41% over the past 6 months, with this year growth rate of 19.96%, compared to 12.40% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 32.90% and 14.20% for the next quarter. Revenue growth from the last financial year stood is estimated to be -14.00%.
10 analysts offering their estimates for the company have set an average revenue estimate of $30k for the current quarter. 10 have an estimated revenue figure of $30k for the next quarter concluding in Jun 2024. Year-ago sales stood $110k and $72k respectively for this quarter and the next, and analysts expect sales will shrink by -72.70% for the current quarter and -58.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.35% over the past 5 years.
VRDN Dividends
Viridian Therapeutics Inc is expected to release its next earnings report between May 07 and May 13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Viridian Therapeutics Inc (NASDAQ:VRDN)’s Major holders
Insiders own 1.02% of the company shares, while shares held by institutions stand at 101.04% with a share float percentage of 102.08%. Investors are also buoyed by the number of investors in a company, with Viridian Therapeutics Inc having a total of 194 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 3.12 million shares worth more than $74.13 million. As of Jun 29, 2023, Blackrock Inc. held 7.14% of shares outstanding.
The other major institutional holder is VR Adviser, LLC, with the holding of over 3.08 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $73.34 million and represent 7.06% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Aug 30, 2023, the former fund manager holds about 4.71% shares in the company for having 2.06 million shares of worth $37.36 million while later fund manager owns 1.38 million shares of worth $32.8 million as of Jun 29, 2023, which makes it owner of about 3.16% of company’s outstanding stock.
